Loading…
Outlook Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -98.5% over 5Y.
today you would have $14.74▼ -98.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.58 | $1.89 | $7.88 | $21.60 | |
| P/S | — | 60.2x | — | — | — |
| P/B | — | — | — | — | 28.1x |
| EPS | -$1.79 | -$4.06 | -$4.80 | -$6.20 | |
| Profit margin | — | -4416.22% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ADCTADC Therapeutics SA | $1.23 | — | — | — | — | $157.03M |
| CLLSCellectis S.A. | $1.56 | — | 2.8x | — | -94.54% | $157.12M |
| KZIAKazia Therapeutics Ltd | $13.58 | — | 4.6x | — | -106.90% | $155.18M |
| BNRBurning Rock Biotech Ltd | $15.08 |
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| ROE | — | — | — | — | -756.04% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 2.2x |
| — |
| -12.82% |
| $158.99M |
| LFMDLifeMD, Inc. | $3.30 | — | 19.8x | — | -515.90% | $159.06M |
| NRXPNRX Pharmaceuticals, Inc. | $3.55 | — | — | — | — | $153.7M |